MICIS Antiplatelet presentation Summary for web pageRight Antiplatelet Therapy 1. Understanding the benefits and risks of specific regimens 2. Understanding the drugs role in different

Introduction

Antiplatelet drugs are widely‐used for the primary and secondary prevention of myocardial infarction, stroke and other cardiovascular events.

Antiplatelet Drugs

• Aspirin

• clopidogrel (Plavix)

• prasugrel (Effient)

• Dipyridamole + aspirin (Aggrenox)

Clopidogrel v. Aspirin

• Evidence supporting aspirin’s efficacy in a variety of clinical settings has existed for more than two decades

• Clopidogrel (Plavix) has been increasingly used since the publication of the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial in 1996

Clopidogrel:Alternative vs. Adjunct to ASA Therapy?

• Interpretation and clinical application of studies can be challenging because dualantiplatelet therapy increases the risk of bleeding, necessitating a careful risk‐benefit analysis.

Newer Drugs:Aggrenox and Effient

• Aggrenox (Dipyridamole combined with aspirin)– management of patients after stroke

• Effient (Prasugrel)– acute coronary syndromes who have undergone

coronary stent insertion• Works in a similar manner as clopidogrel

• Highly Effective

• Associated with Substantial Bleeding Risk

Choosing the Right Antiplatelet Therapy

1. Understanding the benefits and risks of specific regimens

2. Understanding the drugs role in different clinical settings

3. $$$: clopidogrel and combination aspirin and extended‐release dipyridamole are much more expensive than aspirin

Aspirin for the Primary Prevention of Vascular Disease

• Men derive benefit from aspirin from a reduction in MI risk

• Women derive benefit from aspirin from a reduction in ischemic strokes

Meta‐analysis results of randomized trials evaluating aspirin for primary prevention

OutcomeOdds ratio (95% confidence interval) from aspirin v. placebo

Men Women

All cardiovascular events

0.86 (0.78‐0.94) 0.88 (0.7‐0.99)

Ischemic strokes 1.00 (0.72‐1.41) 0.83 (0.70‐0.97)

Myocardial infarction 0.68 (0.54‐0.86) 1.01 (0.84‐1.21)

Cardiovascular mortality

0.99 (0.86‐1.14) 0.90 (0.64‐1.28)

Recent studies of aspirin for primary prevention in patients with diabetes

Trial Name

Who was enrolled?

What was

studied and for

how long?

What was the primary outcome?

What were the main results?

Prevention of vascular events

Risk of major bleeding

Aspirin PlaceboAbsolute

differenceAspirin Placebo

Absolute difference

POPADAD (BMJ 2008)

DM and an ankle‐brachial index of ≤0.99

but no symptomatic

cardiovascular disease

(n=1,276)

aspirin 100 mg daily v. placebo (median

follow‐up 6.7 years)

Fatal or non‐fatal MI, fatal or non‐fatal

stroke or above ankle

amputation for limb ischemia

18.2% 18.3% Not significant

4.4% 4.9% Not significant

JPAD (BMJ 2008)

DM but no symptomatic

cardiovascular disease

(n=2,539)

aspirin 81 or 100 mg

daily v. placebo (median

follow‐up 4.4 years)

Anyatherosclerotic

event

5.4% 6.7% Not significant

0.003 0 Not significant

POPADAD and JPAD

• Evaluated patients with diabetes

• In JPAD, deaths from MI or stroke were significantly reduced in the low‐dose aspirin group

• Neither trial found reductions in vascular events or mortality

No trials have evaluatedclopidogrel monotherapy for the primary prevention of vascular

events.

Risks of Antiplatelet Therapy• In these trials, aspirin increased the risk of

bleeding in both women and men

• The harms of aspirin may outweigh the benefits for many low‐risk primary prevention patients

• U.S. Preventive Services Task Force guidelines on aspirin use for primary prevention recommends an explicit assessment of a patient’s cardiovascular risk before prescribing aspirin for primary prevention.

BOTTOM LINE

• Because of the bleeding risk caused byantiplatelet therapy, aspirin should be prescribed for primary prevention only in patients for whom the benefits of therapy outweigh their harms

• Some patients who receive aspirin for primary prevention (e.g., low‐risk diabetes) may derive less benefit than traditionally believed.

Primary PreventionResources

• www.ahrq.gov/clinic/cvd/aspprovider.htm

• www.med‐decisions.com

• www.westernstroke.org

Assessing CHD Risk in Men

• CHD Risk Calculation Factors– Age

– Gender

– Total Cholesterol

– HDL

– Tobacco Abuse

– Systolic Blood Pressure

– Taking Medications for Blood Pressure

Assessing Stroke Risk in Women

• Stroke Risk Calculation Factors– Gender

– Age

– Systolic Blood Pressure

– Taking Medication for Blood Pressure

– Diabetes

– Tobacco Abuse

– CVD

– Atrial Fibrillation

– Left Ventricular Hypertrophy

Assessing Stroke Risk in Women cont.

• Obesity– Obesity increases Stroke risk by approx 50%

– Obesity is BMI >/= 30

Average monthly price for commonly used antiplatelet agents

Putting it all togetherCondition Recommended Treatment Evidence

Acute coronary syndromes [Unstable angina, non‐ST‐segment elevation MI (NSTEMI), and ST‐segment elevation MI (STEMI)]

CLOPIDOGREL + ASPIRIN for at least 1 year. PRASUGREL + ASPIRIN for 15 months may be a superior alternative for some non‐elderly

ACS patients who have undergone PCI.

CURE, COMMIT, CLARITY, CHARISMA,

CAPRIE, TRITON

Past MI CLOPIDOGREL for high‐risk patients*, ASPIRIN for all others

CHARISMA, CAPRIE

Stable angina ASPIRIN Antiplatelet TrialistsCollaboration,

CHARISMA

Elective PCI CLOPIDOGREL + ASPIRIN for at least a year CREDO

Stroke CLOPIDOGREL or ASPIRIN + DIPYRIDAMOLE MATCH, CHARISMA, ESPS2, ESPRIT,

PRoFESSPeripheral artery disease CLOPIDOGREL CHARISMA, CAPRIE

Primary prevention ASPIRIN only for patients in whom benefits outweigh risks

POPADAD, JPAD, USPSTF

*High risk patients: history of coronary artery disease, stroke, or TIA, and any of the following: bypass surgery, events involving multiple vascular beds, two or more ischemic events, diabetes, or high cholesterol.

Questions?www.mainemed.com